The Minister of Solidarity and Health, the Minister of Higher Education, Research and Innovation and the Secretary General for Investment, announced on Monday the winners of the call for projects "Hospital-University Health Research" (RHU). The Innov-CKD project led by Aix-Marseille University (AMU) and the Assistance Publique - Hôpitaux de Marseille (AP-HM) is among them.
This call for projects was launched by the Agence Nationale de la Recherche (ANR) as part of the future investment programme and aims to support and finance innovative and large-scale research projects in the health sector. From among the 67 applications submitted, an international jury selected 15 winners, including INNOV-CKD coordinated by Aix-Marseille University, which will receive €5,084,421.
Thus, Professor Laurent BONELLO, - Cardiology Department of the North Hospital (AP-HM) - and researchers from the Cardiovascular and Nutrition Research Centre (C2VN), - joint AMU/INSERM/INRA research unit headed by Professor Marie-Christine ALESSI and Professor Françoise DIGNAT-GEORGES, Dean of the Faculty of Pharmacy - will be able to develop personalized treatments for coronary complications in patients suffering from chronic renal disease.
Acute coronary syndrome (ACS), the cause of myocardial infarction, is the obstruction by a clot - or thrombus - of one or more arteries that supply blood to the heart. This disease affects 100,000 people in France and 800,000 in the United States each year. In 20 to 40% of cases, it concerns patients with chronic renal insufficiency (CKD).
The objective of INNOV-CKD is to develop and validate innovative, automated methods that can be used in clinical practice to predict the individual risk of thrombosis and bleeding in patients with CKD.
The result of a collaboration between recognized experts in vascular biology, nephrology and cardiology and leading manufacturers in the production of innovative hemostasis tests, this project joins the two RHU projects already launched in Marseille: PIONEER (Pr Fabrice BARLESI) and EPINOV (Pr Fabrice BARTOLOMEI). This is a fine recognition of the excellence and dynamism of Marseille's clinical research teams.